OOIR: Observatory of International Research

Papers

(The H4-Index of Research and Practice in Thrombosis and Haemostasis is 25. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)

Article	Citations
Avatrombopag for adult chronic primary immune thrombocytopenia: a randomized phase 3 trial in China	89
Reevaluating thromboprophylaxis in COVID-19 outpatients: the case for a targeted, risk-based approach	82
How to use and report data on D‐dimer testing in the COVID‐19 era?	72
PB0815 Involvement of the Nuclear Protein, TC2N, in Regulating VWF Levels in Endothelial Cells	66
PB1117 Congenital Thrombotic Thrombocytopenic Purpura: Identification of Two Heterozygous Mutations in Splice Sites through NGS Sequencing	54
OC 61.3 CS585 is a Novel and Highly Selective IP Receptor Agonist for Prevention of Thrombosis	47
OC 71.4 Management Patterns of Antithrombotics and Outcomes in Patients with Hematological Malignancy and Thrombocytopenia: A Prospective Registry (Matter Study)	44
PB1385 Developing a Stem Cell-Based Model for Glanzmann Thrombasthenia to Explore VWF-GPIb Axis during Megakaryopoeisis	44
OC 03.2 Characterization of Peripheral Monocyte Subsets in a Prospective Cohort of Patients with Acute Stroke Suspicion: Results of BOOST Study	39
OC 42.5 Hemorrhagic Risk of Caplacizumab in the Treatment of Thrombotic Thrombocytopenic Purpura a Pharmacovigilance Study from 2020–2022 FAERS Database	39
PB0957 The Application of Existing Risk Assessment Models (RAMs) to Predict the Occurrence of Venous Thromboembolic Events among Patients with Classic Hodgkin's Lymphoma	38
PB0046 Increased Platelet Activation Demonstrated by Elevated CD36 and P-Selectin Expression in 1-year Post Recovered COVID-19 Patients	38
OC 53.5 Clinical Outcomes in Patients with Acute Pulmonary Embolism Undergoing Ultrasound-Assisted Catheter-Directed Thrombolysis	37
PB0186 Results from BeneGene-1 Study: Prospective Collection of Bleeding Rate in Hemophilia B Patients Prior to Phase 3 Study (BeneGene-2) of Fidanacogene Elaparvovec	36
PB0074 Hyper-Immunoglobulin-CovImmuneTM, Provides a Broader Coverage Against Diverse SARS-CoV-2 Variants Relevant to the COVID-19 Pandemic	36
PB1463 Clinical Predictors of In-Hospital Mortality in Patients with Acute Pulmonary Embolism: 15-Years Experience in a Single Center in Argentina	34
PB0464 Smaller Nadroparin Dose Reductions Required for Patients with Renal Impairment: A Multicenter Study	33
PB1031 Assessment of Coagulation Factor Levels in LVAD Patients Following Temporary Warfarin Reversal with 4F-PCC: KVAD Study	33
PB0386 Increased Platelet Expression of the Transcriptional Suppressor ETV6 Can Be Detected by Immunofluorescence on the Blood Smear and Associates with ETV6-Related Thrombocytopenia	28
OC 74.1 Circulating Biomarkers and Mortality in Atrial Fibrillation: The Reasons for Geographic and Racial Differences in Stroke Study	28
PB0926 Venous Thromboembolism and Risk of Depression in Patients with Hematological Cancer: A Population-Based Cohort Study	28
PB1020 Simultaneous Generation of Thrombin and Plasmin in Patients with Deep Vein Thrombosis and High Levels of Lipoprotein (a)	27
PB1228 Inhibitor Detection in Acquired Hemophilia A: A Comparison between the Nijmegen Modified Bethesda Assay and an Anti-FVIII ELISA	27
OC 45.3 Major Bleeding Event Rates in Patients on Hemodialysis and Peritoneal Dialysis: Results from the International DOPPS and PDOPPS	27
PO16 Hemorrhagic Complications in Patients with Hemophilia A	26

OC 71.5 Reasons for Anticoagulation Failure and Provider Management	25
PB0715 H3 Alters the Behavior of Endothelial Cells In Vitro	25
PB0612 COVID-19: Predictive Value of Methemoglobinemia	25